Received May 5, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (PFIZER-BIONTECH)) | PFIZER\BIONTECH | UNK | — | — |
caught Covid; caught Covid; This is a spontaneous report received from a Consumer or other non HCP. Other Case identifier(s): MOC20260427000004 (Moderna). A patient (age and gender not provided) received BNT162b2 (BNT162B2 NOS), as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "caught Covid". Clinical course: It was reported that two patients mentioned. reported adverse event Information date moderna was made aware of the event or new AE information for AE follow-up (Day 0) on 24Apr2026, relevant medical history (vaccines within the past 4 weeks, medical conditions): state were vaccinated with mNexspike on 20Apr2026. Product details product name: Pfizer, date of administration on 20Apr2026 reporter stated that in the past had received Pfizer's Covid vaccine and then caught Covid, They denies had any other reaction to any Covid vaccine. It was reported that patient received vaccines within the past 4 weeks, medical conditions stated that they were vaccinated with mNexspike on 20Apr2026 and -Product Details- Product: Pfizer vaccine on 20APR2026. The patient did not experience any additional symptoms/events. Medication Details and reason for taking the medicine: Is Moderna authorized to communicate with the patient's / your healthcare provider, No. Patients did not experienced any events with mNexspike. Relatedness of drug to reaction(s)/event(s), source of assessment: Non-Health care professional. Method of assessment: Global Introspection. Batch/lot number is not provided, and it cannot be obtained.; Sender's Comments: The reported events of drug ineffective and COVID-19 are assessed as not related to the administration of BNT162b2, as breakthrough infections can occur despite vaccination and there is insufficient information to establish a causal relationship between the vaccine and lack of efficacy.